Details of Disease

General Information of Disease (ID: DIS78WFB)

Disease Name	Peripheral arterial disease
Synonyms	peripheral artery disease; peripheral arterial disorder; pad
Disease Class	BD4Z: Chronic arterial occlusive disease
Definition	A disorder of the arteries supplying the upper and lower extremity and the visceral organs. This includes the mesenteric arteries, the renal arteries and the aorta and excludes cerebrovascular arterial disease. Patients experience cramping and pain usually in the calves and thighs while walking. The symptoms subside with rest.
Disease Hierarchy	DISLG4XS: Arterial disorder DISXSU1Y: Peripheral vascular disease DIS78WFB: Peripheral arterial disease
ICD Code	ICD-11 ICD-11: BD4Z ICD-10 ICD-10: I73, I73.9 ICD-9 ICD-9: 443 Expand ICD-9 443
Disease Identifiers	MONDO ID MONDO_0005386 MESH ID D058729 UMLS CUI C1704436 MedGen ID 352846 SNOMED CT ID 840580004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Sitagliptin	DMGDKXN	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 14 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PRT-201	DMRLS8X	Phase 3	NA	[2]
VM-202	DMSW80U	Phase 3	NA	[3]
Vonapanitase	DMC02MK	Phase 3	NA	[3]
AKB-9778	DMKNRYH	Phase 2	NA	[4]
ALD-301	DMORO8G	Phase 2	NA	[3]
BAY1193397	DM83IYE	Phase 2	NA	[3]
CVBT-141H	DMYPXQ2	Phase 2	NA	[3]
Plasmin	DMOB1EM	Phase 2	NA	[5]
SB-030	DMKIZ1T	Phase 2	NA	[3]
SDF-1	DM80HOV	Phase 2	NA	[3]
T2c-002	DMJUF5V	Phase 2	NA	[6]
TAL-0500018	DMHK0J1	Phase 2	NA	[3]
TV1001sr	DMO4UZ6	Phase 2	NA	[3]
Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy	DMPNUYZ	Phase 1/2	NA	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 14 Drug(s)

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nano-PGE1	DMVQIWE	Investigative	NA	[7]
SAR-106881	DM2J0UN	Investigative	NA	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 34 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CUBN	TT9YLCR	Limited	Genetic Variation	[9]
SLC25A1	TTTD730	Limited	Biomarker	[10]
DAPK3	TTERVQN	moderate	Biomarker	[11]
DUSP5	TTZN92A	moderate	Biomarker	[12]
LPA	TTU9LGY	moderate	Genetic Variation	[13]
NPPC	TTRK0B9	moderate	Altered Expression	[14]
NPR3	TTWVLS6	moderate	Altered Expression	[14]
ADAMTS5	TTXSU2Y	Strong	Biomarker	[15]
AHSG	TTKF4WV	Strong	Altered Expression	[16]
APOH	TT2OUI9	Strong	Biomarker	[17]
ARSA	TTYQANR	Strong	Biomarker	[18]
BMP2	TTP3IGX	Strong	Altered Expression	[19]
CHRNB4	TTTVAFQ	Strong	Genetic Variation	[20]
CS	TTZA6B3	Strong	Biomarker	[21]
F10	TTCIHJA	Strong	Biomarker	[22]
F11	TTDM4ZU	Strong	Biomarker	[23]
F5	TT1O264	Strong	Genetic Variation	[13]
FABP4	TTHWMFZ	Strong	Biomarker	[24]
FURIN	TTH9WF6	Strong	Biomarker	[25]
GCH1	TTLSWP6	Strong	Altered Expression	[26]
GOT1	TTU507L	Strong	Genetic Variation	[27]
HDAC9	TT8M4E1	Strong	Genetic Variation	[28]
KNG1	TTDJ4MY	Strong	Biomarker	[29]
LPL	TTOF3WZ	Strong	Genetic Variation	[13]
MMP3	TTUZ2L5	Strong	Genetic Variation	[13]
NDUFB9	TTBYJ39	Strong	Genetic Variation	[27]
P2RY12	TTZ1DT0	Strong	Genetic Variation	[30]
PADI4	TTQHAXM	Strong	Biomarker	[31]
RTN4	TT7GXMU	Strong	Altered Expression	[15]
SERPIND1	TT8XSKJ	Strong	Altered Expression	[32]
SLC5A2	TTF8JAT	Strong	Biomarker	[33]
THBS1	TTKI0H1	Strong	Biomarker	[34]
TNIK	TTPB1W3	Strong	Genetic Variation	[27]
UTRN	TTNO1VA	Strong	Genetic Variation	[27]
------------------------------------------------------------------------------------


⏷ Show the Full List of 34 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC6	DT582KR	moderate	Genetic Variation	[35]
SLC2A10	DT3BI6S	Strong	Genetic Variation	[36]
------------------------------------------------------------------------------------

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ABO	DESIA7R	Strong	Genetic Variation	[37]
PCYT1A	DEQYXD4	Strong	Biomarker	[38]
PON3	DETXQZ1	Strong	Biomarker	[39]
UGDH	DE48Q2Z	Strong	Genetic Variation	[27]
------------------------------------------------------------------------------------

This Disease Is Related to 72 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAMTS7	OTVKZ1DV	moderate	Genetic Variation	[40]
ADI1	OT8IOD03	moderate	Biomarker	[41]
ANGPTL6	OTOQ5W67	moderate	Biomarker	[42]
BFAR	OTTBG0V7	moderate	Biomarker	[43]
CASP8AP2	OTTWT68S	moderate	Biomarker	[44]
CETN1	OTGQ8JOZ	moderate	Biomarker	[45]
EIF3K	OTGTKVGO	moderate	Biomarker	[46]
FBLN5	OTLVNZ8U	moderate	Biomarker	[47]
FXYD5	OT81DIOD	moderate	Biomarker	[48]
MFAP4	OT5W64QY	moderate	Biomarker	[49]
PADI2	OTT40K94	moderate	Biomarker	[50]
PRKRA	OTUTVZZU	moderate	Biomarker	[51]
RBBP6	OTTVG4HU	moderate	Biomarker	[51]
SDF4	OTQ7WFYW	moderate	Biomarker	[45]
SOSTDC1	OTAKDNSM	moderate	Biomarker	[52]
TCFL5	OTJL4348	moderate	Genetic Variation	[53]
TET3	OT76U3YF	moderate	Altered Expression	[54]
THBS4	OTA1T9KK	moderate	Biomarker	[55]
ADD1	OTTF68DC	Strong	Genetic Variation	[56]
ADGRG1	OTQBB8NT	Strong	Altered Expression	[57]
AGGF1	OTA7U2T8	Strong	Biomarker	[58]
ANGPTL8	OTQFINCD	Strong	Altered Expression	[59]
ANTXR1	OT5W1GPC	Strong	Biomarker	[60]
BEST1	OTWHE1ZC	Strong	Altered Expression	[61]
BMP8A	OT1997IN	Strong	Biomarker	[27]
CARD16	OT4NUHWB	Strong	Genetic Variation	[62]
CCHCR1	OT22C116	Strong	Biomarker	[63]
CELSR2	OTON6JSZ	Strong	Genetic Variation	[13]
CHRNA3	OTCZQY1U	Strong	Genetic Variation	[20]
CNNM1	OTHRSSGH	Strong	Genetic Variation	[27]
CNOT4	OTM8I5RH	Strong	Genetic Variation	[27]
CNTN3	OTC1274J	Strong	Genetic Variation	[27]
COL4A1	OTL6D1YE	Strong	Genetic Variation	[13]
CREB3L1	OT2JHIHM	Strong	Genetic Variation	[13]
DHX40	OTOL02QN	Strong	Biomarker	[31]
EFHC1	OTS9IBNE	Strong	Genetic Variation	[27]
FAM20C	OTW5YZ7X	Strong	Biomarker	[64]
FEZ1	OTWCXPRE	Strong	Genetic Variation	[27]
FGB	OT6RKLI9	Strong	Genetic Variation	[65]
HARS1	OTHOEOTS	Strong	Biomarker	[66]
HGS	OTCYYCAC	Strong	Biomarker	[66]
IL18BP	OTW0LRYZ	Strong	Altered Expression	[67]
IPO5	OTAK40ED	Strong	Genetic Variation	[28]
LIPC	OTZY5SC9	Strong	Genetic Variation	[68]
LRRTM4	OTYJ4348	Strong	Genetic Variation	[27]
MACF1	OTVIHD77	Strong	Genetic Variation	[27]
MT1B	OTUA4FFH	Strong	Genetic Variation	[69]
MTHFD1L	OTV01EFP	Strong	Genetic Variation	[27]
NSMCE1	OTZJTA5X	Strong	Genetic Variation	[27]
NUS1	OT4DQ82L	Strong	Altered Expression	[15]
OPN4	OT1LZ7TS	Strong	Genetic Variation	[27]
OSBPL10	OT0TFMBE	Strong	Genetic Variation	[70]
PADI1	OT13WAQX	Strong	Biomarker	[71]
PAQR8	OTGZ8W9F	Strong	Genetic Variation	[27]
PPP2R2C	OTXK0SDM	Strong	Genetic Variation	[27]
PPP4R2	OT7FCZRM	Strong	Genetic Variation	[27]
PSMD14	OTJWHMZ5	Strong	Biomarker	[71]
PTCRA	OTQTO5QZ	Strong	Biomarker	[23]
RAP2A	OT0JB5S4	Strong	Genetic Variation	[28]
RBFOX1	OTFPKEL7	Strong	Genetic Variation	[27]
RETN	OTW5Z1NH	Strong	Altered Expression	[72]
RILPL2	OTL2KPRO	Strong	Genetic Variation	[27]
SELENBP1	OT3NZNTR	Strong	Biomarker	[63]
SELENOP	OT02B8IR	Strong	Genetic Variation	[73]
SHBG	OTPWU5IW	Strong	Biomarker	[63]
SPRTN	OT01D5CE	Strong	Genetic Variation	[74]
SRSF5	OTC5WP98	Strong	Biomarker	[66]
SYTL3	OT6TPBA9	Strong	Genetic Variation	[75]
TLR10	OTQ1KVJO	Strong	Genetic Variation	[27]
TRAM2	OTSFG0ST	Strong	Genetic Variation	[27]
TRIM5	OTMZH7EJ	Strong	Genetic Variation	[27]
TRIM63	OTUSWA74	Strong	Biomarker	[76]
------------------------------------------------------------------------------------


⏷ Show the Full List of 72 DOT(s)

References

1	ClinicalTrials.gov (NCT01619332) Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT02110901) A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT02387788) Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Research into therapies derived from stem cells is progressing, despite restrictions. PMLiVE. 5th September 2007.
7	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
9	Cubilin Single Nucleotide Polymorphism Variants are Associated with Macroangiopathy While a Matrix Metalloproteinase-9 Single Nucleotide Polymorphism Flip-Flop may Indicate Susceptibility of Diabetic Nephropathy in Type-2 Diabetic Patients.Nephron. 2019;141(3):156-165. doi: 10.1159/000494391. Epub 2018 Dec 17.
10	Serum carboxy-terminal telopeptide of type I collagen (I-CTP) is predictive of clinical outcome in peripheral artery disease patients following endovascular therapy.Heart Vessels. 2017 Feb;32(2):149-156. doi: 10.1007/s00380-016-0858-2. Epub 2016 Jun 1.
11	Socioeconomic Distressed Communities Index associated with worse limb-related outcomes after infrainguinal bypass.J Vasc Surg. 2019 Sep;70(3):786-794.e2. doi: 10.1016/j.jvs.2018.10.123. Epub 2019 Jun 14.
12	Dual specificity phosphatase 5 regulates perfusion recovery in experimental peripheral artery disease.Vasc Med. 2019 Oct;24(5):395-404. doi: 10.1177/1358863X19866254. Epub 2019 Aug 26.
13	Genome-wide association study of peripheral artery disease in the Million Veteran Program.Nat Med. 2019 Aug;25(8):1274-1279. doi: 10.1038/s41591-019-0492-5. Epub 2019 Jul 8.
14	Endothelial C-Type Natriuretic Peptide Is a Critical Regulator of Angiogenesis and Vascular Remodeling.Circulation. 2019 Mar 26;139(13):1612-1628. doi: 10.1161/CIRCULATIONAHA.118.036344.
15	The role of novel cytokines in inflammation: Defining peripheral artery disease among patients with coronary artery disease.Vasc Med. 2018 Oct;23(5):428-436. doi: 10.1177/1358863X18763096. Epub 2018 Apr 11.
16	Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease.Minerva Med. 2018 Dec;109(6):443-450. doi: 10.23736/S0026-4806.18.05628-8. Epub 2018 Apr 12.
17	Circulating anti-2-glycoprotein I antibodies of peripheral arterial disease patients trigger a genomic overexpression of Toll-like receptor 4 in endothelial cells.J Vasc Surg. 2015 Apr;61(4):1041-9.e1. doi: 10.1016/j.jvs.2013.11.066. Epub 2014 Jan 25.
18	Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.Curr Cardiol Rep. 2019 Aug 30;21(10):115. doi: 10.1007/s11886-019-1198-5.
19	Incremental effects of diabetes mellitus and chronic kidney disease in medial arterial calcification: Synergistic pathways for peripheral artery disease progression.Vasc Med. 2019 Oct;24(5):383-394. doi: 10.1177/1358863X19842276. Epub 2019 May 15.
20	Gene variance in the nicotinic receptor cluster (CHRNA5-CHRNA3-CHRNB4) predicts death from cardiopulmonary disease and cancer in smokers.J Intern Med. 2016 Apr;279(4):388-98. doi: 10.1111/joim.12454. Epub 2015 Dec 22.
21	Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease.Circulation. 1999 Feb 16;99(6):807-12. doi: 10.1161/01.cir.99.6.807.
22	How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?.Kardiol Pol. 2019 Aug 23;77(7-8):661-669. doi: 10.33963/KP.14855. Epub 2019 May 30.
23	Trends in Lower Limb Amputation in Patients with Diabetic Foot Based on Vascular Intervention of Peripheral Arterial Disease in Korea: a Population-based Nationwide Study.J Korean Med Sci. 2019 Jul 8;34(26):e178. doi: 10.3346/jkms.2019.34.e178.
24	Positive Association of Serum Adipocyte Fatty Acid Binding Protein Level With Peripheral Artery Disease in Hemodialysis Patients.Ther Apher Dial. 2020 Jun;24(3):300-306. doi: 10.1111/1744-9987.13431. Epub 2019 Oct 9.
25	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).Circulation. 2017 Apr 11;135(15):1417-1428. doi: 10.1161/CIRCULATIONAHA.116.025707. Epub 2017 Feb 16.
26	Sodium Tanshinone IIA sulfonate improves post-ischemic angiogenesis in hyperglycemia.Biochem Biophys Res Commun. 2019 Dec 10;520(3):580-585. doi: 10.1016/j.bbrc.2019.09.106. Epub 2019 Oct 14.
27	Genetic Variants in the Bone Morphogenic Protein Gene Family Modify the Association between Residential Exposure to Traffic and Peripheral Arterial Disease.PLoS One. 2016 Apr 15;11(4):e0152670. doi: 10.1371/journal.pone.0152670. eCollection 2016.
28	Genome-Wide Association Study of Peripheral Arterial Disease in a Japanese Population.PLoS One. 2015 Oct 21;10(10):e0139262. doi: 10.1371/journal.pone.0139262. eCollection 2015.
29	Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries.Br J Pharmacol. 2019 Feb;176(3):386-399. doi: 10.1111/bph.14534. Epub 2018 Dec 9.
30	Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.Molecules. 2018 Feb 10;23(2):374. doi: 10.3390/molecules23020374.
31	Variability of revascularization techniques among Catalan hospitals and impact on leg salvage in patients with peripheral arterial disease.Int Angiol. 2019 Feb;38(1):54-61. doi: 10.23736/S0392-9590.18.04041-5.
32	Heparin cofactor II as a novel vascular protective factor against atherosclerosis.J Atheroscler Thromb. 2009 Oct;16(5):523-31. doi: 10.5551/jat.1552. Epub 2009 Sep 3.
33	SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?.Curr Probl Cardiol. 2019 Jul;44(7):207-222. doi: 10.1016/j.cpcardiol.2018.06.004. Epub 2018 Jul 6.
34	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.J Cell Mol Med. 2018 Apr;22(4):2086-2097. doi: 10.1111/jcmm.13565. Epub 2018 Feb 14.
35	The prevalence of pseudoxanthoma elasticum: Revised estimations based on genotyping in a high vascular risk cohort.Eur J Med Genet. 2019 Feb;62(2):90-92. doi: 10.1016/j.ejmg.2018.05.020. Epub 2018 May 22.
36	SLC2A10 genetic polymorphism predicts development of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes.BMC Med Genet. 2010 Aug 25;11:126. doi: 10.1186/1471-2350-11-126.
37	Targeted Sequencing Study to Uncover Shared Genetic Susceptibility Between Peripheral Artery Disease and Coronary Heart Disease-Brief Report.Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1227-1233. doi: 10.1161/ATVBAHA.118.312128.
38	A geometry-based model for non-invasive estimation of pressure gradients over iliac artery stenoses.J Biomech. 2019 Jul 19;92:67-75. doi: 10.1016/j.jbiomech.2019.05.030. Epub 2019 May 24.
39	Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease.Atherosclerosis. 2012 Feb;220(2):545-51. doi: 10.1016/j.atherosclerosis.2011.11.021. Epub 2011 Nov 22.
40	Genetic variants rs1994016 and rs3825807 in ADAMTS7 affect its mRNA expression in atherosclerotic occlusive peripheral arterial disease.J Clin Lab Anal. 2018 Jan;32(1):e22174. doi: 10.1002/jcla.22174. Epub 2017 Feb 15.
41	Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease.JAMA. 2018 Feb 27;319(8):807-817. doi: 10.1001/jama.2018.0246.
42	Angiopoietin-related growth factor is independently associated with lower extremity peripheral arterial disease.J Diabetes Complications. 2017 Feb;31(2):433-438. doi: 10.1016/j.jdiacomp.2016.10.019. Epub 2016 Oct 27.
43	A prospective, multi-center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry.Catheter Cardiovasc Interv. 2018 May 1;91(6):1144-1148. doi: 10.1002/ccd.27565. Epub 2018 Mar 7.
44	Free-Breathing Fast Low-Angle Shot Quiescent-Interval Slice-Selective Magnetic Resonance Angiography for Improved Detection of Vascular Stenoses in the Pelvis and Abdomen: Technical Development.Invest Radiol. 2019 Dec;54(12):752-756. doi: 10.1097/RLI.0000000000000592.
45	Platelet-Derived MRP-14 Induces Monocyte Activation in Patients With Symptomatic Peripheral Artery Disease.J Am Coll Cardiol. 2018 Jan 2;71(1):53-65. doi: 10.1016/j.jacc.2017.10.072.
46	Heat therapy improves soleus muscle force in a model of ischemia-induced muscle damage.J Appl Physiol (1985). 2019 Jul 1;127(1):215-228. doi: 10.1152/japplphysiol.00115.2019. Epub 2019 May 30.
47	Adventitial Drug Delivery of Dexamethasone to Improve Primary Patency in the Treatment of Superficial Femoral and Popliteal Artery Disease: 12-Month Results From the DANCE Clinical Trial.JACC Cardiovasc Interv. 2018 May 28;11(10):921-931. doi: 10.1016/j.jcin.2017.12.015. Epub 2018 May 2.
48	Efficacy of Long-Term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial Disease.J Am Heart Assoc. 2019 Jul 2;8(13):e011779. doi: 10.1161/JAHA.118.011779. Epub 2019 Jun 19.
49	Microfibrillar-associated protein 4 variation in symptomatic peripheral artery disease.J Transl Med. 2018 Jun 8;16(1):159. doi: 10.1186/s12967-018-1523-6.
50	Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial).J Surg Res. 2019 Jun;238:164-174. doi: 10.1016/j.jss.2019.01.038. Epub 2019 Feb 13.
51	IN.PACT?Admiral?drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease.Adv Drug Deliv Rev. 2017 Mar;112:69-77. doi: 10.1016/j.addr.2016.10.003. Epub 2016 Oct 19.
52	WIRION Embolic Protection System in Lower Extremity Arterial Interventions: Results of the Pivotal WISE LE Trial.JACC Cardiovasc Interv. 2018 Oct 8;11(19):1995-2003. doi: 10.1016/j.jcin.2018.05.025.
53	CHADS? CHADSASc, and New ABCD Scores Predict the Risk of Peripheral Arterial Disease in Patients with Sleep Apnea.J Clin Med. 2019 Feb 5;8(2):188. doi: 10.3390/jcm8020188.
54	Reduced mRNA and Protein Expression Levels of Tet Methylcytosine Dioxygenase 3 in Endothelial Progenitor Cells of Patients of Type 2 Diabetes With Peripheral Artery Disease.Front Immunol. 2018 Dec 6;9:2859. doi: 10.3389/fimmu.2018.02859. eCollection 2018.
55	Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes.Heart Vessels. 2020 Jan;35(1):52-58. doi: 10.1007/s00380-019-01453-7. Epub 2019 Jun 21.
56	ADD1 460W allele associated with cardiovascular disease in hypertensive individuals.Hypertension. 2002 Jun;39(6):1053-7. doi: 10.1161/01.hyp.0000019128.94483.3a.
57	Acute and chronic effects of exercise on mRNA expression in the skeletal muscle of two mouse models of peripheral artery disease.PLoS One. 2017 Aug 3;12(8):e0182456. doi: 10.1371/journal.pone.0182456. eCollection 2017.
58	Angiogenic factor AGGF1 promotes therapeutic angiogenesis in a mouse limb ischemia model.PLoS One. 2012;7(10):e46998. doi: 10.1371/journal.pone.0046998. Epub 2012 Oct 23.
59	Associations Between Plasma Betatrophin Levels and Coronary and Peripheral Artery Disease.J Atheroscler Thromb. 2019 Jun 1;26(6):573-581. doi: 10.5551/jat.46508. Epub 2018 Dec 4.
60	Anthrax Toxin Receptor 1 Is Essential for Arteriogenesis in a Mouse Model of Hindlimb Ischemia.PLoS One. 2016 Jan 19;11(1):e0146586. doi: 10.1371/journal.pone.0146586. eCollection 2016.
61	Lower Extremity Peripheral Arterial Disease Is an Independent Predictor of Coronary Heart Disease and Stroke Risks in Patients with Type 2 Diabetes Mellitus in China.Int J Endocrinol. 2017;2017:9620513. doi: 10.1155/2017/9620513. Epub 2017 May 8.
62	Gait deficiencies associated with peripheral artery disease are different than chronic obstructive pulmonary disease.Gait Posture. 2017 Sep;57:258-264. doi: 10.1016/j.gaitpost.2017.06.018. Epub 2017 Jun 27.
63	Cohort Study Examining the Association Between Blood Pressure and Cardiovascular Events in Patients With Peripheral Artery Disease.J Am Heart Assoc. 2019 Mar 19;8(6):e010748. doi: 10.1161/JAHA.118.010748.
64	Peripheral artery disease, redox signaling, oxidative stress - Basic and clinical aspects.Redox Biol. 2017 Aug;12:787-797. doi: 10.1016/j.redox.2017.04.017. Epub 2017 Apr 13.
65	Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde.Circulation. 1996 Feb 1;93(3):440-9. doi: 10.1161/01.cir.93.3.440.
66	Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease.J Cardiovasc Pharmacol. 2009 Dec;54(6):520-5. doi: 10.1097/FJC.0b013e3181bfadfd.
67	Increased IL18 mRNA levels in peripheral artery disease and its association with triglyceride and LDL cholesterol levels: a pilot study.Heart Vessels. 2016 Jun;31(6):976-84. doi: 10.1007/s00380-015-0753-2. Epub 2015 Oct 5.
68	Association of the -250G/A promoter polymorphism of the hepatic lipase gene with the risk of peripheral arterial disease in type 2 diabetic patients.J Diabetes Complications. 2008 Jul-Aug;22(4):273-7. doi: 10.1016/j.jdiacomp.2007.06.011. Epub 2008 Apr 16.
69	The MTP -493TT genotype is associated with peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) Study.Clin Biochem. 2008 Jun;41(9):712-6. doi: 10.1016/j.clinbiochem.2008.02.007. Epub 2008 Feb 21.
70	Identification of evidence suggestive of an association with peripheral arterial disease at the OSBPL10 locus by genome-wide investigation in the Japanese population.J Atheroscler Thromb. 2010 Oct 27;17(10):1054-62. doi: 10.5551/jat.4291. Epub 2010 Jul 2.
71	Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease.J Surg Res. 2017 Apr;210:124-131. doi: 10.1016/j.jss.2016.11.011. Epub 2016 Nov 11.
72	Leptinemia is Associated With Peripheral ArteryDisease.J Surg Res. 2019 Jun;238:48-56. doi: 10.1016/j.jss.2019.01.023. Epub 2019 Feb 6.
73	Associations and interactions between variants in selenoprotein genes, selenoprotein levels and the development of abdominal aortic aneurysm, peripheral arterial disease, and heart failure.PLoS One. 2018 Sep 6;13(9):e0203350. doi: 10.1371/journal.pone.0203350. eCollection 2018.
74	DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
75	Variants Associated with the Ankle Brachial Index Differ by Hispanic/Latino Ethnic Group: a genome-wide association study in the Hispanic Community Health Study/Study of Latinos.Sci Rep. 2019 Aug 6;9(1):11410. doi: 10.1038/s41598-019-47928-5.
76	TLR-4 and VEGF polymorphisms in chronic periaortitis.PLoS One. 2013 May 14;8(5):e62330. doi: 10.1371/journal.pone.0062330. Print 2013.